MedTrace Logo

NeuroRegen Scaffold™ With Stem Cells for Chronic Spinal Cord Injury Repair

NCT02352077 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-12-23

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of NeuroRegen scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) in patients with chronic spinal cord injury.

Conditions

  • Spinal Cord Injury

Interventions

BIOLOGICAL

NeuroRegen scaffold with BMMCs or MSCs transplantation

Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.

Sponsors & Collaborators

  • Affiliated Hospital of Logistics University of CAPF

    collaborator OTHER

  • The First Affiliated Hospital of Soochow University

    collaborator OTHER

  • First Hospitals affiliated to the China PLA General Hospital

    collaborator OTHER_GOV

  • Chinese Academy of Sciences

    lead OTHER_GOV

Principal Investigators

  • Jianwu Dai, Ph.D · Chinese Academy of Sciences

  • Sai Zhang, M.D · Affiliated Hospital of Logistics Universtiy of CAPF

  • Huilin Yang, Ph.D · The First Affiliated Hospital of Soochow University

  • Shuxun Hou · First Hospitals affiliated to the China PLA General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02352077 on ClinicalTrials.gov